{"analyses":[{"ciLowerLimit":"0.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.86","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment A over Treatment B","nonInferiorityType":"SUPERIORITY","pValue":"0.0006","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalMethod":"Log-rank test stratified"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.24","upperLimit":"16.16","value":"14.13"},{"groupId":"OG001","lowerLimit":"9.46","upperLimit":"12.45","value":"10.74"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab + Ipilimumab + Chemotherapy","id":"OG000","title":"Treatment A"},{"description":"Chemotherapy only","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of death (assessed up to October 2019, approximately 23 months)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}